Core Insights - ReShape Lifesciences has been granted an international patent for its Diabetes Neuromodulation technology, which aims to improve glycemic control in Type 2 diabetes patients [1][2] - The patent, valid until December 4, 2039, supports the company's proprietary vBloc™ technology, which combines vagus nerve block and stimulation [1][2] - The technology has shown promise in reducing medication reliance for diabetics, potentially lowering treatment costs and complications [2] Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band® and Obalon® systems [4] - The company has a strong intellectual property portfolio with 62 issued or pending patents related to vagal neuromodulation and glucose control [2] - ReShape is in the process of selling its assets, including the Lap-Band® and Obalon® systems, to Biorad Medisys, which will also acquire the DBSN™ system [5] Technology Details - The ReShape Diabetes Neuromodulation system is a minimally invasive implant that utilizes bio-electronic neuromodulation to regulate plasma glucose levels [3] - The system works by stimulating pancreatic vagus celiac fibers to release insulin while blocking the hepatic vagal branch to decrease glucose release [3] - Pre-clinical studies have demonstrated increased glycemic control in animal models of Type 2 diabetes [2][3]
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology